Skip to main content

Melanotan I vs Semax

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Melanotan I

Melanotan I (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe sun sensitivity.

Full details →

Semax

Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.

Full details →

Side-by-Side Comparison

AspectMelanotan ISemax
MechanismBinds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection without UV exposure.Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning.
Typical DosageClinical: 16mg implant every 2 months. Research protocols for tanning typically use 0.5-1mg daily for loading, then maintenance dosing.Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery.
AdministrationFDA-approved form is a subcutaneous implant. Research use involves subcutaneous injection. Often combined with minimal UV exposure to enhance results.Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency.
Side EffectsNausea (especially initially), facial flushing, fatigue, headache, and darkening of existing moles or freckles.Generally well-tolerated. May cause mild irritability or hair shedding in some users.
Best For

Key Differences

Unique to Melanotan I:

Unique to Semax:

Detailed Analysis

Melanotan I and Semax are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Melanotan I for Skin Health & Aesthetics. Choose Semax for Cognitive Performance.

Ready to Learn More?